Navigation Links
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Date:7/24/2008

the patient's thigh. From this muscle specimen, autologous myoblasts (muscle stem cells) are then isolated, grown using Bioheart's proprietary cell-culturing process, and injected directly into the scar tissue of the patient's heart. The myoblast cells are delivered via an endoventricular needle-injection catheter during a minimally invasive procedure performed by an interventional cardiologist or vascular surgeon. The myoblast-based muscle formation in the newly populated regions of scar tissue are intended to improve cardiac function by helping the heart muscle beat more efficiently.

ABOUT BIOHEART, INC.

Bioheart, Inc. (Nasdaq: BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more informat
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
4. GeoVax Reports Progress on Its AIDS Vaccine Technology
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
7. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
10. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)Opposes use of imported drugs often stored in tin cans and car trunks ,, WASHINGTON, Dec. 4 Today, the senior advocacy group RetireSafe urged the Senate to defeat the Dorgan Importation plan encomp
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2Linkwell Corporation Announces Launch of the Series of Handwashing Contest Across China 55285 1Linkwell Corporation Announces Launch of the Series of Handwashing Contest Across China 55285 2Linkwell Corporation Announces Launch of the Series of Handwashing Contest Across China 55285 3B Braun Named Supplier of the Year by McKesson 55284 1B Braun Named Supplier of the Year by McKesson 55284 2Hospice Foundation of America Presents New Educational Webinar on Supporting People with Intellectual Disabilities through Illness Grief and Loss 55282 1Hospice Foundation of America Presents New Educational Webinar on Supporting People with Intellectual Disabilities through Illness Grief and Loss 55282 2Hospice Foundation of America Presents New Educational Webinar on Supporting People with Intellectual Disabilities through Illness Grief and Loss 55282 3
...on six products from Pharmion,s pipeline provide s...ncluding promising Phase III,data on use of Thalid...ay 31, 2007 /PRNewswire-FirstCall/ -- Pharmion,Cor...s of studies,investigating the company,s marketed ...ed at the American Society of Clinical,Oncology,s ...
...ARY, June 01, 2007 /PRNewswire-FirstCall/ - Resear...colytics") are,scheduled to deliver a poster prese...t the American Society of Clinical Oncology,(ASCO)...ago. The,data cover final results of Oncolytics, U...oster, entitled "Final Results of a Phase I Study ...
Other Medicine Technology:Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2
...ield changes so rapidly that by the time students ...dical knowledge. //In an effort to address this is... Medicine adjusted its curriculum 13 years ago, an... skills beyond the medical licensing exam," said K...
...nts of funds Eden Medical Center a health affiliat...has finalized //its decision to call off its progr...rvices to Medi-Cal beneficiaries hitherto made ava...ther hospitals for specific services informed the ...
...ce with a drug called AZD2171 which reduced the s...ope // that it could someday soon be used in human...Research UK have been published in the journal Car...preventing tumours. Nearly 950,000 cases of ...
... therapy used to help reduce adverse events associ...e the risk of death for smokers admitted to// the ...d at CHEST 2006, the 72nd annual international sci...ent therapy (NRT) during their stay had a higher r...
...ll be able to do away with invasive breast reconst... stem cells //extracted from their own fat, sugges...estigating the potential these cells may have for ...roscopic scaffold structures will enable the produ...
...ption of beer and other alcohol beverages can play...he risk of several serious //diseases, including c...e disorders and osteoporosis, according to medical..., “Beer: To Your Health!” convened by the Universi...
Other Medicine News:Health News:Problem-Based Learning Curriculum a Success for Medical School 2Health News:Problem-Based Learning Curriculum a Success for Medical School 3Health News:Smoking Cessation Therapy May be Harmful for ICU Patients 2Health News:Breast reconstruction may be possible with fat stem cells 2Health News:Daily Moderate Consumption of Beer May be Healthy 2
Disposable Filter-Tips, 1100 l (960)
300 L Filter Barrier Pipette Tip
ART 250E
...otic Certified Tips for its full line of 96- and 3...he highest quality, PerkinElmer Robotic Certified ...led accuracy in high throughput applications. Tips...ume range from 0.5 L to 235 L. Tips for 384-channe...
Medicine Products: